These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 30604493)

  • 61. Self-expandable sirolimus-eluting stents compared to second-generation drug-eluting stents for the treatment of the left main: A propensity score analysis from the SPARTA and the FAILS-2 registries.
    Montefusco A; D'Ascenzo F; Gili S; Smolka G; Chieffo A; Baumbach A; Escaned J; Sganzerla P; Tomassini F; Secco GG; Ugo F; Tamburino C; Nicolino A; Mancone M; Poli A; Yew KL; Cirillo P; Wanha W; Pastormerlo LE; di Summa R; Sardella G; Colombo A; Gaita F; Cortese B
    Catheter Cardiovasc Interv; 2019 Feb; 93(2):208-215. PubMed ID: 30298593
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A new generation of biodegradable polymer-coated sirolimus-eluting stents for the treatment of coronary artery disease: final 5-year clinical outcomes from the CREATE study.
    Han YL; Zhang L; Yang LX; Liu HL; Qu P; Li WM; Jiang TM; Li SM; Jing QM; Zhang QY; Xu B; Li Y; Gao RL
    EuroIntervention; 2012 Nov; 8(7):815-22. PubMed ID: 23171802
    [TBL] [Abstract][Full Text] [Related]  

  • 63. 5-Year Safety and Efficacy of Resolute Zotarolimus-Eluting Stent: The RESOLUTE Global Clinical Trial Program.
    Yeh RW; Silber S; Chen L; Chen S; Hiremath S; Neumann FJ; Qiao S; Saito S; Xu B; Yang Y; Mauri L
    JACC Cardiovasc Interv; 2017 Feb; 10(3):247-254. PubMed ID: 28109872
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Long-term clinical impact of polymer-free sirolimus-eluting stents in unselected patients.
    Sinha N; Rai H; Cassese S; Kumar S; Kapoor A; Kastrati A
    Coron Artery Dis; 2016 Aug; 27(5):385-90. PubMed ID: 27124380
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The prognostic utility of the SYNTAX score on 1-year outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial.
    Garg S; Serruys PW; Silber S; Wykrzykowska J; van Geuns RJ; Richardt G; Buszman PE; Kelbæk H; van Boven AJ; Hofma SH; Linke A; Klauss V; Wijns W; Macaya C; Garot P; DiMario C; Manoharan G; Kornowski R; Ischinger T; Bartorelli A; Van Remortel E; Ronden J; Windecker S
    JACC Cardiovasc Interv; 2011 Apr; 4(4):432-41. PubMed ID: 21511223
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Outcomes Among Diabetic Patients Undergoing Percutaneous Coronary Intervention With Contemporary Drug-Eluting Stents: Analysis From the BIONICS Randomized Trial.
    Konigstein M; Ben-Yehuda O; Smits PC; Love MP; Banai S; Perlman GY; Golomb M; Ozan MO; Liu M; Leon MB; Stone GW; Kandzari DE
    JACC Cardiovasc Interv; 2018 Dec; 11(24):2467-2476. PubMed ID: 30573057
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Differential Prognostic Effect Between First- and Second-Generation Drug-Eluting Stents in Coronary Bifurcation Lesions: Patient-Level Analysis of the Korean Bifurcation Pooled Cohorts.
    Lee JM; Hahn JY; Kang J; Park KW; Chun WJ; Rha SW; Yu CW; Jeong JO; Jeong MH; Yoon JH; Jang Y; Tahk SJ; Gwon HC; Koo BK; Kim HS
    JACC Cardiovasc Interv; 2015 Aug; 8(10):1318-1331. PubMed ID: 26315734
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A propensity score-matched comparison of biodegradable polymer vs second-generation durable polymer drug-eluting stents in a real-world population.
    Zhao YJ; Teng M; Khoo AL; Ananthakrishna R; Yeo TC; Lim BP; Loh JP; Chan MY
    Cardiovasc Ther; 2018 Apr; 36(2):. PubMed ID: 29316284
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Clinical outcomes of real-world patients treated with an amphilimus polymer-free stent versus new generation everolimus-eluting stents.
    Panoulas VF; Latib A; Naim C; Sato K; Ielasi A; Tespili M; Godino C; Testa L; Bedogni F; Colombo A
    Catheter Cardiovasc Interv; 2015 Dec; 86(7):1168-76. PubMed ID: 26269415
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Randomized Comparison of a Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent With a Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention: The SORT OUT VII Trial.
    Jensen LO; Thayssen P; Maeng M; Ravkilde J; Krusell LR; Raungaard B; Junker A; Terkelsen CJ; Veien KT; Villadsen AB; Kaltoft A; Tilsted HH; Hansen KN; Aaroe J; Kristensen SD; Hansen HS; Jensen SE; Madsen M; Bøtker HE; Berencsi K; Lassen JF; Christiansen EH
    Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27412869
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Randomized comparison of novel biodegradable polymer and durable polymer-coated cobalt-chromium sirolimus-eluting stents: Three-Year Outcomes of the I-LOVE-IT 2 Trial.
    Song L; Li J; Guan C; Jing Q; Lu S; Yang L; Xu K; Yang Y; Xu B; Han Y;
    Catheter Cardiovasc Interv; 2018 Feb; 91(S1):608-616. PubMed ID: 29322619
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?: A Pre-Specified Analysis From the ZEUS Trial.
    Ariotti S; Adamo M; Costa F; Patialiakas A; Briguori C; Thury A; Colangelo S; Campo G; Tebaldi M; Ungi I; Tondi S; Roffi M; Menozzi A; de Cesare N; Garbo R; Meliga E; Testa L; Gabriel HM; Ferlini M; Vranckx P; Valgimigli M;
    JACC Cardiovasc Interv; 2016 Mar; 9(5):426-36. PubMed ID: 26965932
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Predictors of clinical outcomes after coronary implantation of bioresorbable polymer sirolimus-eluting Ultimaster stents in all-comers: A report of 1,727 cases.
    Tadano Y; Kotani JI; Kashima Y; Hachinohe D; Watanabe T; Sugie T; Kaneko U; Kobayashi K; Kanno D; Fujita T
    Catheter Cardiovasc Interv; 2019 Jul; 94(1):91-97. PubMed ID: 30636371
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent for the treatment of de novo coronary lesions: Final five-year results of the patient-level pooled analysis from the TARGET I and TARGET II trials.
    Li C; Guan C; Zhang R; Yang Y; Ma C; Li H; Chen S; Han Y; Xu B; Gao R;
    Catheter Cardiovasc Interv; 2019 Feb; 93(S1):818-824. PubMed ID: 30565397
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Biodegradable Polymer Biolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With Coronary Artery Disease: Final 5-Year Report From the COMPARE II Trial (Abluminal Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent).
    Vlachojannis GJ; Smits PC; Hofma SH; Togni M; Vázquez N; Valdés M; Voudris V; Slagboom T; Goy JJ; den Heijer P; van der Ent M
    JACC Cardiovasc Interv; 2017 Jun; 10(12):1215-1221. PubMed ID: 28579236
    [TBL] [Abstract][Full Text] [Related]  

  • 76. 2-Year Clinical Outcomes of an Abluminal Groove-Filled Biodegradable-Polymer Sirolimus-Eluting Stent Compared With a Durable-Polymer Everolimus-Eluting Stent.
    Xu B; Saito Y; Baumbach A; Kelbæk H; van Royen N; Zheng M; Morel MA; Knaapen P; Slagboom T; Johnson TW; Vlachojannis G; Arkenbout KE; Holmvang L; Janssens L; Ochala A; Brugaletta S; Naber CK; Anderson R; Rittger H; Berti S; Barbato E; Toth GG; Maillard L; Valina C; Buszman P; Thiele H; Schächinger V; Lansky A; Wijns W;
    JACC Cardiovasc Interv; 2019 Sep; 12(17):1679-1687. PubMed ID: 31129092
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Impact of diabetes on clinical outcomes after revascularization with sirolimus-eluting and biolimus-eluting stents with biodegradable polymer from the SORT OUT VII trial.
    Ellert J; Christiansen EH; Maeng M; Raungaard B; Jensen SE; Kristensen SD; Veien KT; Junker AB; Jakobsen L; Aarøe J; Terkelsen CJ; Kahlert J; Villadsen AB; Bøtker HE; Jensen LO
    Catheter Cardiovasc Interv; 2019 Mar; 93(4):567-573. PubMed ID: 30244533
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Real-world reasons and outcomes for 1-month versus longer dual antiplatelet therapy strategies with a polymer-free BIOLIMUS A9-coated stent.
    Gallone G; D'Ascenzo F; Boccuzzi G; Cortese B; Di Biasi M; Omedè P; Capodanno D; Cerrato E; Vicinelli P; Infantino V; Poli A; Ugo F; Conrotto F; Grigis G; Varbella F; Latini RA; D'Urbano M; Montabone A; Senatore G; Ferrara E; D'Amico M; De Ferrari GM; Ielasi A
    Catheter Cardiovasc Interv; 2020 Sep; 96(3):E248-E256. PubMed ID: 32012453
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable-Polymer Everolimus-Eluting Stent for Percutaneous Coronary Revascularization: 2-Year Results of the BIOSCIENCE Trial.
    Zbinden R; Piccolo R; Heg D; Roffi M; Kurz DJ; Muller O; Vuilliomenet A; Cook S; Weilenmann D; Kaiser C; Jamshidi P; Franzone A; Eberli F; Jüni P; Windecker S; Pilgrim T
    J Am Heart Assoc; 2016 Mar; 5(3):e003255. PubMed ID: 26979080
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.